The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer treatment without chemotherapy.

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...

A breakthrough in CAR-T therapy may allow cancer treatment with a single injection, cutting costs and making care more available.

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

HaemaLogiX earlier this week announced it has received TGA approval to commence a Phase 1 clinical trial of its KMCAR™ CAR-T cell therapy targeting multiple myeloma, marking a key milestone for the ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

SHANGHAI, March 19 (Reuters) - AstraZeneca said on Thursday it will build a cell therapy manufacturing and supply base and an ...